Noliprel-induced cardiac and renal morphofunctional changes in patients with arterial hypertension

The objective of the study was to examine the effects of noliprel on renal hemodynamics and to establish correlations in the vascular regions of the heart and kidneys. The authors performed a 0-month open randomized study that included 35 patients (9 males and 26 females) aged 40 to 65 years (mean 55.8 ± 7.8 years) who had grades 1 and 2 arterial hypertension (AH). Blood pressure (BP), the rigidity of large arteries, cardiac remodeling, total peripheral vascular resistance, and renal blood flow were monitored during therapy. All studies were performed before and о months alter therapy. Results: The target BP (< 140/90 mm Hg) was achieved in 88.0 % оf the patients by the end of the sixth month. The drug was found to have a positive effect on cardiac remodeling reductions in the thickness of the interventricular septum (by 9.9 %), the relative thickness of the walls (by 4.5 %), the left ventricular myocardial mass index (LVMMI) (by 9.5 %) and an increase in the E/A ratio from (0.8 ± 0.07 to 1.1 ± 0.08 (p < 0.01). Noliprel therapy decreased renal resistance indices (RI) (particularly at the level of the ostium of renal arteries and interlobar renal arteries) - RI reduced by 5.9 and 9.2 respectively ( p < 0.01) and Pi decreased by 2.5 and 9.7 % (p < 0.01), reduced the systolic/diastolic ratio (p < 0,01), and significantly increased renal blood flow velocities. There was a direct relationship of the renal indices of peripheral resistance to the rigidity of large arteries, mean and pulse BP, LVMMI, and total peripheral vascular resistance. Conclusion. The results of the study confirm that there is an early cardiovascular remodeling (primarily damages to the most important target organs the heart and kidneys) in patients with mild and moderate hypertension. Noliprel therapy reduced the peripheral resistance of large and minor vessels, diminished myocardial hypertrophy, and recovered left ventricular diastolic function. Noliprel improves renal blood flow due to diminished peripheral vascular resistance at the level of the ostium of renal arteries, the renal portal and intrarenal vessels, which suggests that the drug has renal protective properties.

arterial hypertension, cardiovascular remodeling, noliprel

1. Моисеев В.С., Кобалава Ж.Д. Комбинированная фармакотерапия артериальной гипертонии. Сердце. 2002; 1 (5): 228-31.

2. Goidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Hypertension 2003; 21: 1011-53.

3. Оганов Р.Г., Небиеридзе Д.В. Клиническая эффективность нолипрела при лечении артериальной гипертонии. Основные результаты исследования ЭТАЛОН. Кардиология 2004; 3: 66-9.

4. Castaigne Aю, Chalmers J., Morgan T. et al. Efficacy and safely of an oral fixed low-dose perindopril 2 mg/indapamide 0,625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild-to moderate hypertension. Clin Exp Hypertens 1999; 21: 1097-110.

5. Chalmers J., Castaigne A., Morgan T., Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as the first-line therapy in elderly hypertensive patients. J Hypertension 2000: 18: 327-37.

6. Channdet X., Phong Chau N., De Champvallins M. Very-low-dose perindopril 2mg/indapamide 0,625 mg combination gives higher response and normalization rates than losartan 50 mg in the treatment of essential hypertension. Am J Hypertension 2000; 4: 140A.

7. Morgan T., Anderson A. Low-dose combination therapy (perindopril, indapamide) compared with irbesartan monotherapy. J Hypertension 2001: 19 (Suppl.2): 235.

8. Галеева З.M., Галявич А.С. Влияние фиксированной низкодозовой комбинации гипотензивных препаратов на клинико-биохимические характеристики больных артериальной гипертензией. Артериальная гипертензия 2003; 9 (6): 221-4.

9. De Luca N., Safar M.E. Efficacy of a very-low-dose perindopril 2mg/indapamide 0,625 mg on cardiac hypertrophy in hypertensive patients: the REASON project. J Hypertension 2002; 20 (4).

10. Asmar R., London G., Benetos A. et al. The REASON project: blood pressure evaluation. Am J Hypertension 2001; 14: 115A.

11. Asmar R., London G.M., O'Rourke M.E. et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril, indapamide combination in hypertensive patients. A comparison with atenolol. J Hypertension 2001:38: 922-6.

12. Mogensen C.E., Viberti G., Halimi S. et al. Treatment based on low-dose combination of perindopril and indapamide reduces albuminuria more effectively than enalapril in hypertensive type 2 diabetic patients. J Hypertension 2002: 15: 21A-22A.

13. Rakusan K., Cicutti N., Maurin A. et al. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stoke-prone spontaneously hypertensive rats. Microvasc Res 2000; 59: 243-54.

14. Hayakawa H., Coffee K., Raij L. Endothelial dysfunction and cardiioreual injury in experimental salt-sensitive hypertension. Effect of antihypertensive therapy. Circulation 1997; 96: 2407-13.

15. Лелюк В.Г., Лелюк С.Э. Ультразвуковая ангиология М: Реальное время, 2003.

16. Мареев В.Ю. Сердечно-сосудистый континуум. Сердечная недостаточность 2002: 3 (1): 7-11.

17. Шляхто Е.В. Патогенез гипертонической болезни. Сердечная недостаточность 2002; 3 (1): 12-4.

18. Маколкин В.И., Подзолков В.И., Павлов В.И., Самойленко В.В. Состояние микроциркуляции при гипертонической болезни. Кардиология. 2003; 5. 60-6.

19. Чазова И.Е. Российская многоцентровая программа ПРИЗ - изучение антигипертензивной эффективности и переносимости периндоприла в широкой клинической практике. Consilium medicum. 2002; 4 (3): 125-9.

20. Bocker W., Hupt H. et al. Effects of indapamide in Rats with Pressure overload Left ventricular Hypertrophy. J Cardiovasc Pharmacol 1995; 25: 973-8.

21. Del Rio M., Chulia T., Merchan-Perez A. et al. Effects of indapamide on atherosclerosis development in cholesterol fed rabbits. J Cardiovasc Pharmacol 1995; 25: 973-8.

22. Mirroneau J., Savineau J.P., Mirroneau C. Effects of indapamide on the electromechanical properties of rat myometrium and rat portal rem. J Pharmacol Exp Thear 1986; 236: 519-25.

23. Juaguerto D.C., Schini V.B., Vanboutte P.M. Indapamide potentiales the endothelium depend production of cyclic guanosin monophosphate by bradykinine in the canine femoral artery. Am Heart 1991; 122 (2): 1204-9.

24. Richard V., Joamides R., Неnrу J.P. et al. Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats: haemodynamic, biological and structural effects. J Hypertension 1996; 14 (12): 1447-57.

25. Лопатин Ю.М., Иваненко В.В., Семенова Н.В. и др. Влияние фиксированной низкодозовой комбинации периндоприла и индапамида на процессы сердечно-сосудистого моделирования у ранее не леченных пациентов с артериальной гипертонией. Кардиология 2004; 5: 48- 53.